ASX 200 healthcare stocks gaining momentum

These ASX healthcare stocks offer strong upside potential supported by impressive clinical milestones and several upcoming catalysts.

Proteomics International Laboratories Limited (ASX: PIQ)

Proteomics International Laboratories Limited has surged over 24% year-to-date and recently announced that its US Reference Laboratory has secured CAP accreditation which represents a major regulatory milestone that supports faster commercialisation in the United States.
The company on 17 December 2025 announced that it had secured a United States patent for its proprietary PromarkerEso blood test which is designed for the early detection of esophageal adenocarcinoma (EAC) where 90% of cases are diagnosed at a late stage.

Proteomics International also confirmed the successful installation and commissioning of a new precision diagnostics mass spectrometry platform which enhances its testing and research capabilities.

Cash receipts from customers for the September quarter were $1.86 million which marked a significant increase from $0.20 million in the June quarter and was due to a one-off $1.71 million receipt associated with the WA Proteomics Facility partnership.

As at 30 September 2025, the company reported cash reserves of $10 million along with receipt of a $2.2 million Research and Development tax incentive rebate in November.

The company is in the process of implementing testing protocols for the planned United States launch of PromarkerEso in 2026 which could serve as a catalyst.

Microba Life Sciences Limited (ASX: MAP)

Microba Life Sciences Limited on 3 December 2025 announced that it received a $3.06 million R&D Tax Incentive refund for FY25 which strengthens its financial position alongside $13.9 million in cash and equivalents reported at the end of Q1 FY26.

In Q1 FY26, core test volumes increased 145% year-on-year to 4,931 tests with the global annualised run rate approaching 20,000 tests which places the business on track for regional break even in Australia and the United Kingdom.

Revenue quality improved as growth product revenue rose 151% year-on-year while disciplined cost control led to operating expenditure falling by more than 26% compared to the prior quarter.
During the period, the company delivered several operational milestones which included new MetaXplore product feature releases, brand consolidation initiatives and continued expansion of clinician adoption across Australia and the UK.

From an investment perspective, Microba presents asymmetric upside as a capital efficient diagnostics platform with proven clinical traction supported by a solid cash runway and lower execution risk.

PYC Therapeutics Limited (ASX: PYC)

on 19 December 2025 announced that its Phase 1a/1b clinical trial of PYC-003 for Polycystic Kidney Disease met key safety objectives with single doses up to 4 mg/kg found to be safe and well tolerated in healthy volunteers.

The company also confirmed that dosing of PKD patients has commenced and that it is preparing to initiate repeat dosing in the first half of 2026 which supports a clear pathway towards a registrational Phase 2/3 study.

Beyond PKD, PYC is focused on three additional clinical-stage programs which are Phelan-McDermid Syndrome, Retinitis Pigmentosa Type 11 and Autosomal Dominant Optic Atrophy, with human efficacy data expected across all four programs over the next 24 months.
As of 30 September 2025, the company held $135 million in cash with an additional $20 million expected in Q1 2026 attributable to the FY25 R&D rebate.

The outlook is driven by multiple upcoming catalysts across 2026 and 2027, including repeat-dose data, efficacy readouts and regulatory engagement.

(Source: Company Reports)